Recombinant peptide and protein biosimilars, built for global supply.
Our innovator-aligned microbial platforms deliver the purity, scale, and regulatory confidence global pharmaceutical partners need.
Proprietary platforms, built to advance high-barrier recombinant biosimilars
Proprietary Platforms
- Proprietary microbial expression systems, led by YESTIDE™
- Yeast-based platform engineered for recombinant peptide and protein biosimilars
- Spanning GLP-1, insulin, and immunology
Proprietary platforms, built to advance high-barrier recombinant biosimilars
Proprietary Platforms
- Proprietary microbial expression systems, led by YESTIDE™
- Yeast-based platform engineered for recombinant peptide and protein biosimilars
- Spanning GLP-1, insulin, and immunology
A focused pipeline of high-value recombinant biosimilars.
Our growing portfolio of recombinant biosimilar programs across GLP-1, insulin, and immunology spans various stages of development with confirmed FTO in key global markets and structured pathways for licensing and supply.
Manufacturing capabilities
Pre-Seed Bioreactor (100L) x2
Seed Bioreactor (1000L) x4
Production Bioreactor (10000L) x5
Continuous Centrifuge
Downstream Purification
Preparative Chromatography
R&D Capabilities
Sequence & Construct Engineering
Multi-Host Expression Platforms
Strain / Clone Development
Cell Banking & Stability Systems
Media & Seed Train Optimization
Scalable Fermentation Development
Analytical Capabilities
UHPLC
HPLC-UV/PDA
LC–MS
HRMS
SEC-HPLC
qPCR
P.V.S.N. Raju
Chairman & MD
Seasoned Entrepreneur & Engineering Excellence
P. Akhilesh Raju
Chief Executive Officer
MBA · Anglia Ruskin
Dr. T Devi Kalyan
Chief Operating Officer
PhD · DRDO
Harmeet Lamba
Advisor
MBA · Wharton BS
Dr. Manpreet Singh
Vice President, BD
PhD · NIPER
